Neurocrine launches Parkinson's therapy as COVID-19 related disruptions ease

Neurocrine Biosciences Inc on Monday launched its add-on treatment for patients with Parkinson's disease nearly five months after Food and Drug Administration's approval, as the COVID-19 pandemic delayed its roll out in the United States.